An article published Nov. 7 on Technical420, a website tracking cannabis stocks and investments, expresses high hopes to make big profits once Germany legalizes pot. “For more than a year, we have discussed how Germany could create a domino type effect for legal cannabis in the EU and our hypothesis is already starting to prove to be accurate.” Last week, it continued “the Czech coalition government reported to be drafting a bill to regulate the cannabis industry. This comes after the government appointed drug commissioner Jindřich Vobořil to draft a law to legalize adult-use cannabis.” The site then zooms in on how U.S. billionaire Peter Thiel’s front firm Tilray Brands (see slug) is leading the offensive:
“• Germany—By acquiring Aphria, Tilray Brands enhanced its leverage to the German cannabis market and we are bullish on that market.
“• Italy—Tilray Medical was approved to start importing and distributing its medical cannabis oral solution in Italy.
“• Portugal—During the first calendar quarter of 2021, Tilray Portugal was approved to export Good Manufacturing Processes (GMP) certified medical cannabis from Portugal to Spain.
“• Poland—in mid-August, Tilray Brands received approval to commercialize branded medical cannabis products in Poland which further expands its product offering and distribution across pharmacies in Europe.
“• Spain—In early 2021, Tilray started to sell medical cannabis to patients in Spain.
